Introduction
Gold nanoparticles (AuNPs) are one of the most investigated metal nanoparticles. [1, 2] They have attracted considerable interest in various applications such as catalysis, [3, 4] medical diagnosis, [5] biological sensors, [6] drug delivery [7, 8] and imaging. [9] Many types of ligands have been studied as stabilizers in the synthesis of organic and water soluble AuNPs: besides thiols, other examples found in the literature include thioether end-functionalized polymers, [10] dendrimers, [11] amino acid based amphiphiles, [12] peptides, [13] DNA, [14] and ionic liquids based on imidazolium salts. [15] In particular, the use of derivatives of pyridine such as 4-(dimethylamino)pyridine (DMAP), [16] [17] [18] dihydropyridine [19] and pyridinium salts [20, 21] as stabilizing agents of AuNPs has been reported although the definitive stabilization mechanism is not yet fully established.
On the other hand, our group has reported previously the preparation and stabilization of monodisperse gold nanoparticles using gemini imidazolium-based amphiphiles. [22, 23] These molecules show anion binding properties in solution, and therefore they play a unique triple role, acting as phase transfer agent of the gold salt during the synthesis, capping agent for the stabilization of the AuNPs, and binding agent for anionic molecules, resulting in a major simplification of the synthetic process and subsequent purification of the functional nanomaterial. [22] Furthermore, the ability of bis-imidazolium salts to complex anions, [24] particularly carboxylates, allowed the incorporation and delivery of a carboxylate-containing model drug. [22, 25] As a step forward in this research we have focused on the use of gemini amphiphiles based on bispyridinium salts in the synthesis of AuNPs, expecting that these molecules would expand the anion recognition ability of the nanomaterials. To test the AuNPs' ability to incorporate and release anionic molecules, two model drugs were used: ibuprofen and piroxicam, which are non-steroidal anti-inflammatory drugs widely used in inflammatory arthritis and osteoarthritis. [26] The gemini pyridinium salts used in this work are formed by two pyridinium rings linked by a 1,3-dimethylenebenzene spacer. This spacer was chosen based in analogue compounds that contain pyridinium moieties rather than imidazolium. Therefore, to study the effect of the spacer (length and flexibility) lies beyond the scope of the present work.
Thus, we report here (a) a solution based preparation of new AuNPs (organic and water-soluble AuNPs) with bis-pyridinium amphiphilic ligands, which act both as transfer agents of gold into organic media and also as nanoparticle stabilizers, (b) the formation of AuNPs by reduction of Au 3+ by the spontaneous oxidation of a bis-tetrahydropyridine amphiphile, (c) their chemical and physical characterization, including their stability in solution toward aggregation and ligand exchange, (d) toxicity data concerning both the bis-pyridinium ligands and the bis-pyridinium coated nanoparticles, (e) their molecular recognition ability toward piroxicam and ibuprofen, as models of anionic drugs, (f) in vitro studies of the ability of the new AuNPs for delivering anionic pharmaceuticals.
Experimental Section

Materials
Sodium hydrogen carbonate, sodium sulfate (Na2SO4) and 6N hydrochloric acid (HCl) were purchased from Scharlau; sodium hydroxide (NaOH) from Merck, 4-methylpyridine, 1,3-bis(bromomethyl)benzene, 1-decanol, 1-octadecanol, 4-chloropyridine hydrochloride, hydrogen peroxide (H2O2), sodium borohydride (NaBH4), hydrogen tetrachloroaurate (III) (HAuCl4), sodium citrate tribasic dihydrate, potassium bromide (KBr), ibuprofen, piroxicam, tetraoctylammonium bromide, phosphate buffered saline (PBS) pH=7.4 and 5.2 were purchased from Sigma-Aldrich. Metallic sodium and ammonia 20 % were purchased from Panreac and hexa(ethylene glycol)alkyl thiol (HS-C11-(EG)6-OH) was purchased from Prochimia. Acetonitrile (MeCN), dichloromethane (CH2Cl2), methanol (MeOH), diethyl ether (Et2O), chloroform (CHCl3), ethanol (EtOH), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), dimethylformamide (DMF), toluene, dimethylsulfoxide-d6 (CD3)2SO and chloroform-d (CDCl3)
were purchased from Sigma-Aldrich.
Methods
Melting points were measured by CTP-MP 300 hot-plate apparatus with ASTM 2C thermometer using crystal capillaries purchased from Afora. 1 Nanotecnologia (ICN2)-CSIC in a Phoibos 150 analyzer (SPECS GmbH, Berlin, Germany)) in ultra-high vacuum conditions (base pressure 5E-10 mbar) with a monochromatic aluminium Kalpha x-ray source (1486.74eV). ). The energy resolution as measured by the FWHM of the Ag 3d5/2 peak for a sputtered silver foil was 0.58 eV. Thermogravimetric Analysis was performed on
Mettler Toledo TGA/SDTA 851e from CCiT-UB, from 30 °C to 700 °C with a heating rate of 10 °C min -1 . Capsules: crucible of aluminum (100 μL) with perforated cap. Nitrogen was used as purgative gas in all measurements.
Synthesis and characterization of the ligands 1·2Br and 2
1,3-Bis(4-octadecyloxy-1-piridiniomethyl)benzene dibromide (1·2Br): The synthesis of the precursor of 1·2Br followed a modification of a protocol previously reported, [28] where metallic sodium (1.86 g, 80 mmol) was added to 1-octadecanol (21.9 g, 80 mmol) at 110 °C for 2 h. Then 4-chloropyridine hydrochloride (4.95 g, 33 mmol) was added and the mixture was stirred for 72 h at 110 °C. After cooling down to room temperature, water (50 mL) was added dropwise and the solution neutralized with HCl 6N. The aqueous phase was extracted with CH2Cl2 (4 x 25 mL), and the organic phase was dried with anhydrous Na2SO4 and the solvent was evaporated in vacuum.
The residue was purified using a silica gel column chromatography using Et2O/CH2Cl2 
Synthesis and characterization of AuNPs
Synthesis of 1·AuNPs with the bis-pyridinium salt 1·2Br
A solution of HAuCl4 (11.8 mg, 0.03 mmol) in water (0.5 mL) and a 1% solution of trisodium citrate dihydrate (15 mg, 0.05 mmol) in water (1.5 mL) were added to boiling water (10 mL).
Heating was continued for 15 min. during which time the solution changed colour from pale yellow to red. The reaction flask was allowed to cool to room temperature. Then, an aqueous solution of these AuNPs (8 mL) was mixed with a solution of ligand 1·2Br (24 mg, 0.025 mmol) in CHCl3 (8 mL). The biphasic mixture was stirred for 24 h in the dark at room temperature. The phases were separated and the solvent of the organic phase was removed in a rotary evaporator, and the residue washed using centrifugation in EtOH (3 x 1 mL), to give 1·AuNPs.
Synthesis of 2·AuNPs with the bis-pyridinium salt 1·2Br
An aqueous solution of HAuCl4 (8.8 mg, 0.026 mmol) in water (2 mL) was mixed with a solution of 1·2Br (50 mg, 0.052 mmol) in CHCl3 (2 mL). After 1 h, a solution of NaBH4 (4.9 mg, 0.13 mmol) in water (2 mL) was slowly added. The stirring continued for 4 h in the dark at room temperature. The organic phase of the resulting dark red solution was separated and the solvent was removed in a rotary evaporator, and the residue washed using centrifugation in EtOH (5 x 1 mL), to afford 2·AuNPs.
2.4.3.
Synthesis of 3·AuNPs and 4·AuNPs using the bis-pyridinium salt 1·2Br and the thiol
HS-C11-(EG)6-OH
A solution of HAuCl4 (3.6 mg, 0.009 mmol) in water (0.5 mL) was added to a stirred solution of 1·2Br (4.3 mg, 0.005 mmol) in CHCl3 (0.5 mL). Then, a solution of the thiol HS-C11-(EG)6-OH (2.1 mg, 5 μmol) in CHCl3 (0.5 mL) was added. An excess of NaBH4 (5.1 mg, 0.14 mmol) in water (1 mL) was added dropwise to the mixture. The stirring continued for 24 h in the dark at room temperature. AuNPs were obtained in both phases (organic and aqueous phase). The water-soluble AuNPs were named 3·AuNPs and the organic-soluble AuNPs were named 4·AuNPs. The phases were separated and the solvent of aqueous phase (3·AuNPs) and organic phase (4·AuNPs) was removed in a rotary evaporator, and the residues washed using centrifugation in EtOH (5 x 1 mL).
Synthesis of 2'·AuNPs with the tetrahydropyridine 2.
A solution of 2 (50 mg, 62 μmol) in CHCl3 (2 mL) was added to a solution of KBr (15.3 mg, 0.13 mmol) in water (2 mL). Then a solution of HAuCl4 (1.8 mg, 0.005 mmol) in water (2 mL) was added dropwise to the mixture. The stirring continued for 3 h in the dark at room temperature. The phases were separated and the organic solvent was removed in a rotary evaporator, and the residue washed using centrifugation in EtOH (5 x 1 mL), to afford 2'·AuNPs.
Results and Discussion
The compounds synthesized in this work are bis-pyridinium salts connected through a 1,3-xylyl spacer; the pyridinium moieties bear chains of different length: 1·2Br (18 carbon atoms) ( Figure   1 ), 3·2Br (10 carbon atoms) and 4·2Br (1 carbon atom) (see Supplementary Material Figure S1 ), to assess the influence of the chain length on the synthesis and stability of the AuNPs where they will be incorporated. The three bis-pyridinium salts 1·2Br, 3·2Br and 4·2Br were synthesized in good yield (see Supplementary Material Scheme S1). Salts 1·2Br and 3·2Br were obtained in two steps by reaction of 4-chloropyridine hydrochloride with aliphatic alcoxides, either from 1-octadecanol or 1-decanol, affording the corresponding alkoxypyridines, [28] which were the limiting step, since they were difficult to purify. The alkoxypyridines reacted with 1,3-bis(bromomethyl)benzene to afford 1·2Br (94 %) and 3·2Br (83 %), respectively. Also, the tetrahydropyridine 2 was obtained in 88 % in yield by treatment of bis-pyridinium salt 1·2Br with an excess of NaBH4 ( Figure 1 and Scheme S1 in Supplementary Material). The bis-pyridinium salt Table 1 .
Firstly, we synthesized AuNPs using the bis-pyridinium salt 1·2Br to study their capacity as stabilizer agent. Thus, 1·AuPs were obtained by a two-step procedure, consisting of the preparation of citrate stabilized NPs (using a modification of Turkevich method [29] ), followed by mixing with a solution of the ligand 1·2Br for 24 h (Table 1 entry On the other hand, the synthesis following a modification of AuNPs using the same bis-pyridinium salt 1·2Br as stabilizing agent and the biphasic Brust-Schiffrin protocol [30] resulted in a red solution, the so-formed AuNPs are named 2·AuNPs here (Table 1 , entry 2). In this case, the reducing agent NaBH4 converts the pyridinium salt to the tetrahydropyridine 2, and therefore a 1·2Br 2 Br mixed coating is expected for 2·AuNPs (Scheme 1). These results confirm the capacity of 1·2Br
as stabilizer agent as well as transfer agent in the synthesis of the 1·AuNPs and 2·AuNPs.
Additionally, the stability of 2·AuNPs was determined in solution at room temperature and under reflux in three different solvents (CHCl3, THF and toluene), by means of UV-vis absorption spectroscopy. No obvious change in the shape of the maximum in the plasmon resonance peak was observed, which indicates that the prepared 2·AuNPs are stable (Supplementary Material Section 3 Table S1 ).
One concern during the synthesis of these AuNPs is the chemical integrity of the bis-pyridinium salt 1·2Br under the reaction conditions used, especially in the presence of NaBH4 as the reducing agent, because the reduction could lead to the formation of tetrahydropyridine species that could influence the stability of the AuNPs. The mechanism of the reduction of pyridinium salts by sodium borohydride to give tetrahydropyridine and piperidine derivatives has been well established. [31, 32] It is known that dihydropyridines can act as coatings in the formation of stable gold nanoparticles, [19] while for tetrahydropyridines, to the best of our knowledge, have not been reported yet.
To obtain water soluble AuNPs, with potential to be used in biomedical applications, some attempts were made to use both ligands in a monophasic system, but no AuNPs could be obtained, and therefore we chose to use a biphasic system adapted from the Brust-Schiffrin method.
Basically, the AuNPs preparation consisted of mixing of the gemini pyridinium based amphiphilic ligand 1·2Br and a thiolated polyethyleneglycol derivative HS-C11-(EG)6-OH in CHCl3 for the formation and coating of AuNPs, and then adding the aqueous HAuCl4 solution and the reducing agent (NaBH4). Following this method, it was possible to obtain two types of AuNPs: Watersoluble AuNPs named 3·AuNPs and organic-soluble AuNPs named 4·AuNPs (Table 1 , entry 3).
The different hydrophilicity of 3·AuNPs and 4·AuNPs may originate on the relative proportion of both stabilizers, obviously with 3·AuNPs having a higher content on HS-C11-(EG)6-OH, but the exact proportion of each could not be exactly determined. The obtained 3·AuNPs and 4·AuNPs will allow to study the incorporation and interaction with different anionic drugs such as ibuprofen and piroxicam and their respective sodium salts (see later).
To confirm which species, either pyridinium salt 1·2Br or its reduced form 2, is stabilizing the gold surface, we encompassed different experiments (Table 1 entries 4 and 5). First, we attempted the synthesis of AuNPs using the tetrahydropyridine 2 following a modification of the BrustSchiffrin method but in the absence of the reducing agent NaBH4. Under these conditions, the bistetrahydropyridine 2 is capable of reducing Au +3 to Au 0 , concomitantly to its spontaneous oxidation to the corresponding bis-pyridinium salt, leading to the formation of nanoparticles, which were unstable in solution as indicated by the formation of a dark precipitate after 24 h (Table   1 , entry 4). However, when the tetrahydropyridine 2 was used in the presence of an excess of KBr (Table 1 , entry 5), stable 2'·AuNPs soluble in organic solvents were obtained. The stabilization of the metallic core by reduced 2 is proven by the fact that nanoparticles are not stable when synthetized from 2 with no addition of an excess of KBr. Additionally, the excess of pyridinium salts 1·2Br that are not coating the AuNPs, and therefore remains free in solution, is rapidly reduced to tetrahydropyridine 2 by action of the NaBH4 used as reducing agent, likely resulting in a formation of a bilayer around the pyridinium salts, although the exact disposition of 2 is not exactly determined. Due to the fact that the tetrahydropyridine does not have charges, these AuNPs are not water-soluble. If a 1·2Br bilayer was formed, the AuNPs would be water-soluble. These experiments indicate that the stabilizing species around the gold core in the AuNPs is the ion pair formed by either bromide or citrate ions, attached to the gold particle surfaces, and the cationic surfactant head groups (gemini pyridinium salt) surrounding the anion layer by electrostatic interactions. This conclusion arises from the fact that when no enough bromide ions anions are present, i.e. when using only the tetrahydropyridine 2, the obtained AuNPs are not On the other hand, to study the influence of the length chain of the ligands on the stabilization of the AuNPs, we selected bis-pyridinium salts with shorter hydrocarbon chains: 3·2Br and 4·2Br (see Supplementary Material Figure S1 ). The synthesis of AuNPs using the bis-pyridinium salt 3·2Br was attempted following a modification of the Brust-Schiffrin method [30] (see Supplementary Material Section 4 Table S2 , entry 6). In the case of 4·2Br, the preparation of the AuNPs was attempted by a modification of the Turkevich method [29] using different reduction agents such as NaBH4 [34] , H2O2 [35, 36] or citrate [29] (see Supplementary Material Table S2 , entries 7-10). In all cases, using 3·2Br or 4·2Br did not yield any AuNPs, as no formation of the typical red solution was observed, and a precipitate was visible in some cases. Clearly, the length of the chain of the bis-pyridinium salt, 18 carbon atoms in 1·2Br is decisive for the amphiphile to act as promoter agent, and thus to successfully generate AuNPs. Consequently, the use of 3·2Br
and 4·2Br for the synthesis of AuNPs was not further studied. The samples observed by HRTEM were prepared by depositing onto a carbon-coated copper grid the solutions of AuNPs with concentration range between 4x10 -4 -5x10 -2 µM. Figure 3 shows the micrographs obtained for 1·AuNPs-4·AuNPs and 2'·AuNPs and their respective histograms. In all cases, the nanoparticles display a spheroidal shape and low polydispersity ( Table 2 ). The samples of 1·AuNPs showed the biggest size and lowest polydispersity, which may be due to the selected synthesis method using a Turkevich protocol. Colloids 2·AuNPs and 4·AuNPs showed the highest polydispersity with an average size between 5 and 17 nm, while in the cases of 3·AuNPs and 2'·AuNPs an average size between 9-13 nm was observed (Table 2) . with the fact that this technique measures the hydrodynamic size of the particles, in contrast with HRTEM that only gives us the gold core size, because no contrast agent was used and the ligands used are transparent to the electron beam compared with the gold. Thus, the size measured by DLS gives the diameter that includes not only the core but also the alkyl chains of the ligands. 1·AuNPs
showed the highest value of size (23.5 nm), this result may be due to the selected synthesis method, as it is known that the AuNPs synthesized by Turkevich method present a bigger size than the AuNPs synthesized by Brust-Schiffrin method. On the other hand, the values of the size obtained by DLS were similar for 2·AuNPs and 2'·AuNPs nanoparticles, this may be because both have a similar composition, while in the case of 3·AuNPs and 4·AuNPs were bigger, this may be due to the presence of S-PEG on the surface of AuNPs, which leads to increase the diameter of the nanoparticles.
NMR spectroscopy. NMR spectroscopy was used to complement the information about the species coating the different AuNPs, and the results are in good agreement with those observed by MALDI-ToF-MS. The 1 H NMR spectra of 1·AuNPs, acquired in CDCl3 at room temperature exhibit signals corresponding to the bis-pyridinium salt 1·2Br (see Supplementary Material Figure   S22 ). In contrast, in the cases of the 2·AuNPs and 2'·AuNPs, the signals corresponding to the tetrahydropyridine 2 were observed (see Supplementary Material Figure S23 and S24, respectively). Table 3 (see also Supplementary Material Table S3 and Figure S25 -S29, respectively). The spectra were recorded using DHB as the matrix. Despite precedents from the literature reports, [22, 23, 25] on bis-imidazolium coated nanoparticles, the experimental conditions for recording sufficiently informative spectra were difficult to find. As we can see in Table 3 and   Table S3 see Supplementary Material, all nanoparticles but 1·AuNPs have multicomponent coatings. In the case of 2·AuNPs and 2'·AuNPs there is indication of the presence of both ligands 1·2Br or 2, peaks arising from the tetrahydropyridine 2 being the most abundant, together with peaks resulting from the fragmentation of 1·2Br (see Supplementary Material Table S3 ). These results can be explained in terms of the redox processes taking place during the synthesis of the AuNPs leading to the existence of both species in the mixed coatings, i.e. reduction of 1·2Br by NaBH4 in the case of 2·AuNPs, or spontaneous oxidation of 2 in the case of 2'·AuNPs. Obviously, for 1·AuNPs, synthesized using citrate as the reducing agent, only peaks associated to the bispyridinium salt 1·2Br can be observed; specifically, peaks corresponding to its the molecular ion (m/z 957.6) ( Table 3) or peaks resulting from its fragmentation (Table S3 in the Supplementary Material); the fragments reveal complexation to gold, indicating close proximity to the surface of the nanoparticle metallic core. For multicomponent colloids 3·AuNPs and 4·AuNPs the most abundant peaks indicate the presence of both 1·2Br and the thiolated polyethyleneglycol derivative as the predominant species, although in the case of 4·AuNPs, the tetrahydropyridine 2 was also present, something that could explain the higher hydrophobicity of these nanoparticles because of the absence of charge in the reduced surfactant. Figure S30 ). In the case of the 2'·AuNPs it was not possible to observe the signals corresponding to Au 0 not even after the sputtering step, probably because the coating tetrahydropyridine 2. In the case of 2'·AuNPs, 2 forms an extremely compact bilayer around the monolayer of the pyridinium salt, which difficult the extraction of the organic layer without completely destroying the sample.
Thermogravimetric Analysis (TGA). 2·AuNPs was further characterized by TGA, to confirm the presence of both ligands in these GNP. The thermogram of 2·AuNPs showed the presence of both 1·2Br and the correspondingly reduced 2 (see Supplementary Material Section 5 Figure S31 ).
TGA also allowed determination of the mass ratio for the two ligands (1·2Br and 2) and gold in the analysed 2·AuNPs samples, as stated in (Supplementary Material Table S4 ). Taking into account their respective molecular weights, we could determine the number of moles for each species, and establish a ratio of stabilizer to gold. Furthermore, considering the size of the gold core in 2·AuNPs, the number of gold moles per nanoparticle was determined, and with the ratio stabilizer: gold, the number of ligands per nanoparticle was calculated. Also, after calculating the nanoparticle's surface area the presence of ca. 14 molecules of 1·2Br and 19 molecules of 2 per nm 2 was estimated (see Supplementary Material Figure S31 and Table S4 ). This density is similar to the previously reported AuNPs incorporating gemini imidazolium amphiphiles as stabilizer agents. [22, 25] Overall, it seems to confirm that the minority ligand 1·2Br forms a layer around the gold core, so that the formed 2·AuNPs have the positively charged pyridinium heads layer favouring stabilization of the gold core, and the tetrahydropyridine 2 forms a layer around the bispyridinium salt 1·2Br. This particular disposition would explain why 1·2Br could not be noticeably detected by MALDI-ToF MS and 1 H NMR spectroscopy.
Cytotoxicity and genotoxicity assay of 1·2Br, 2·AuNPs and 3·AuNPs
The cytotoxicity and genotoxicity of ligand 1·2Br as well as 2·AuNPs and 3·AuNPs were studied, since these AuNPs will be used later in the drug release study (see later). The cytotoxicity (expressed here as IC50) was determined in three different cell lines; the mouse fibroblast cell line (3T3/NIH), the human liver carcinoma cell line (HepG2) and the human epithelial colorectal adenocarcinoma cell line (CaCo-2). The cells were exposed to a range of concentrations of ligand 1·2Br, 2·AuNPs and 3·AuNPs for 24 h. The coated AuNPs after to interact with the cell medium, no agglomeration or turbidity was observed, indicating that the synthetized gold nanoparticles 2·AuNPs and 3·AuNPs were stably dispersed in the cell medium for the cytotoxicity test. After exposure, the viability of the cell culture was calculated using the MTT Assay, and the percentage of viable cells was determined as shown in the Supplementary Material Section 6 (Tables S5-S7 ).
The IC50 concentration values calculated for ligand 1·2Br as well as for 2·AuNPs and 3·AuNPs
are shown in Table 4 . The IC50 values found from 2·AuNPs and 3·AuNPs were lower than the IC50 value obtained for the amphiphiles 1·2Br alone. These results suggests that the interaction of the polar head group with the gold nucleus of the nanoparticles prevents, in some way, a higher toxicity, presumably because the positive charge of the pyridinium salt is shielded from interaction with the cell. [37, 38] In the case of 2·AuNPs, they were not cytotoxic for any cell line used, whereas 3·AuNPs showed very low toxicity in HepG2 and CaCo-2 at high concentrations (418 µM and 10460 µM, respectively). Comparison of the values found in the literature for cytotoxicity of gold nanoparticles is hampered by the different experimental protocols reported for its evaluation, as well as for the differences in the composition of the nanomaterials, for which a precise composition is not always defined. [39] Several reports indicate that interaction with the biological media depends on many factors, such as size, shape and charge of gold nanoparticles. [40] Additionally, the moderate toxicity of cationic particles has been evaluated, [41] with the toxicity mainly attributed to the cationic surfactant used as coating agent.
[42] Table 4 . Values of the IC50 determined for the products tested in three different cell lines. The maximum concentration tested was 500 µg/mL. To be suitable for drug delivery purposes, the carriers themselves must be biocompatible and present low toxicity. In our work, it was found that these AuNPs (2·AuNPs and 3·AuNPs), showed low toxicity in three studied cell lines, since the values found for the IC50 were ca. 0.5-1 mM.
Products
These are very high values taking into consideration they are well above the expected concentrations to be administered, which means that the AuNPs should be safe.
Additionally, to evaluate the genotoxicity of 1·2Br, 2·AuNPs and 3·AuNPs in three cell line (3T3/NIH, HepG2 and CaCo-2), the Single Cell Gel Electrophoresis, also known as Comet Assay, was used according to guidelines. [43] For this analysis, cell viability higher than 70 % was required and a genotoxic effect was considered for tail intensity values higher than 10 %. The DNA-damaging alkylating-agent methylmethane sulfonate (MMS 400 mM) was used as positive control. Table S5-S7 in the Supplementary Material show the percentage of tail intensity referring to the DNA fragmentation in the presence of amphiphile 1·2Br, 2·AuNPs and 3·AuNPs, at the same range of concentrations used for testing their cytotoxicity. It was observed that neither 1·2Br nor the AuNPs (2·AuNPs and 3·AuNPs) show any significant formation of a tail of cellular DNA fragments within the studied concentrations and cell lines tested, which means that below the IC50 no genotoxicity is observed (see Supplementary Material Tables S5-S7) , confirming the suitability of these nanomaterials for drug delivery purposes.
Incorporation of ibuprofen and piroxicam into different AuNPs (organic and water soluble)
Prior to the incorporation study of ibuprofen and piroxicam into different AuNPs was study the complexation ability of the bis-pyridinium amphiphile 1·2Br to ibuprofen and piroxicam was examined in solution, using 1 H NMR spectroscopy. The binding of 1·2Br with piroxicam appears to be the stronger as indicated by the observed chemical shifts (see Supplementary Material Section 7 Figure S32 and Table S8 ).
The synthesis of 5·AuNPs and 6·AuNPs (see Supplementary Material Section 8 Figure S33 ) was necessary to use as control nanoparticles in the incorporation study of drugs such as ibuprofen, piroxicam and their respective sodium salts (see later). In both cases, the obtained 5·AuNPs and 6·AuNPs display a spheroidal shape and low polydispersity ( Figure S34 and Table S9 in the Supplementary Material Section 8).
After evaluation of the anion binding exhibited by the pyridinium salt 1·2Br, we decided to investigate if the binding ability was still operating in the AuNPs prepared in this work. Initially, the anion binding properties of 2·AuNPs, 3·AuNPs, 4·AuNPs, as well as the non-pyridinium containing controls 5·AuNPs and 6·AuNPs were studied by UV-vis absorption spectroscopy.
The quantification of ibuprofen and piroxicam were carried out by UV-vis absorption spectroscopy, and used to evaluate the incorporation of these drugs into water soluble 3·AuNPs and 5·AuNPs; their corresponding sodium salts (ibuprofen sodium salt and piroxicam sodium salt), were incorporated into organic-soluble 2·AuNPs, 4·AuNPs and 5·AuNPs.
The results of drug incorporation in different nanoparticles are shown in Table 5 . Control extraction experiments using only solvent as the extraction phase (without any nanoparticles)
indicated that, the quantity of drug in solution was similar to that obtained in the initial solution.
These results indicated that the solvent (H2O/CHCl3) does not interfere with the incorporation of drugs into nanoparticles.
In the case of 2·AuNPs (organic-soluble AuNPs), the percentage of piroxicam sodium salt incorporated to them was greater than ibuprofen sodium salt (Table 5) , possibly because of the higher affinity between piroxicam sodium salt and the ligand 1·2Br as the study of drug-ligand interaction by NMR had shown.
A similar trend is observed for the AuNPs with both ligand 1·2Br and the pegylated thiol (3·AuNPs and 4·AuNPs), which showed higher values of incorporated piroxicam or piroxicam sodium salt rather than either ibuprofen or its sodium salt.
At this point, a control was performed with nanoparticles 5·AuNPs and 6·AuNPs, incorporating only the pegylated thiol, but not the gemini-pyridinium salt 1·2Br. The incorporation of the piroxicam drug was evaluated showing extremely low percentages of incorporation in both nanoparticles 5·AuNPs and 6·AuNPs with values of 8 and 25 %, respectively, indicating that 1·2Br present in the nanoparticles is by far the main responsible for the incorporation of the drug in the nanoparticles synthesized 2·AuNPs, 3·AuNPs and 4·AuNPs. Accordingly, the bis-pyridinium salt 1·2Br containing nanoparticles 3·AuNPs (water-soluble) and 4·AuNPs (organic-soluble) were used for in vitro studies of piroxicam or piroxicam sodium salt.
In order to know the concentration of 3·AuNPs and 4·AuNPs we applied calculations described This means that the drug was well incorporated into the nanoparticles, and that the pyridinium ligands can bind enolate incorporating compounds. Also, a slight change in the SPR peak of the AuNPs was registered, that initially was at 518 nm and shifted to 522 nm for 3·AuNPs and 519
nm and shifted to 528 nm for 4·AuNPs. It is known that the SPR peak depends not only of the size of the AuNPs but also of the ligand that is covering the AuNPs, so we could explain this shift because of the incorporation of the drug (piroxicam and its sodium salt) in the structure. According to our calculations, we could incorporate 50 μg of piroxicam/mg in 3·AuNPs and 46 μg of piroxicam sodium salt/mg in 4·AuNPs.
Finally, the stability of the water soluble 3·AuNPs after the incorporation of piroxicam was studied for a period of three months, and no macroscopic changes in the colloidal dispersions or variations in the SPR band were observed, which indicates that their stability was not affected after the incorporation of the drug (see in the Supplementary Material Table S10 ).
In vitro release studies
The release of piroxicam from the AuNPs was determined using a Franz cells system as schematic representation is included in Figure S36 in the Supplementary Material Section 1.
[45] The samples were suspended in Sorensen buffer at either pH 5.5 or 7.4, to simulate physiological conditions, and the receptor solution used was NaOH 71 mM, in which piroxicam is soluble, as tested prior to the experiments, and thus complying with the SINK conditions. Given the size of the gold nanoparticles, dialysis membranes were selected with a cut-off which allows the passage of piroxicam (molecular weight 331.35 Da) but prevents the passage of the nanoparticles (membrane dialysis pore diameter is equivalent to 2.4 nm).
Six different kinetic models (zero order, first order, Plateau followed by a first order , KorsmeyerPeppas, Higuchi and Weibull function) were used to fit the experimental data obtained in the drug release experiments following the corresponding equations (see Table S11 At physiological conditions the drug release followed a first order kinetics (Figure 4) , with values of the dissociation constant KD of 0.0129 h -1 and 0.0100 h -1 from 3·AuNPs and 4·AuNPs, respectively. At pH 5.5, the same kinetics were observed, and the dissociation constant found were 0.0095 h -1 and 0.0034 h -1 from 3·AuNPs and 4·AuNPs, respectively.
Additionally, the amodelistic parameters (efficiency, medium dissolution time (MDT) and area under curve (AUC)) were calculated (Supplementary Material Section 10, Table S12 ). Therefore, Student´s t-test analysis was performed and significant differences were found between the releases at the pH 5.5 and 7.4 (see Supplementary Material Table S13 ). At pH 7.4 the efficiency of the release is higher than at pH 5.5 in both AuNPs (3·AuNPs and 4·AuNPs), meaning that it is more suited for delivery under physiological conditions and not for an external application in the skin since a higher amount of drug can be released from the AuNPs. On the other hand, the value of MDT registered at pH 7.4 is lower, suggesting that the release of this drug from the AuNPs complex is favoured at this pH. Moreover, in the case of the water-soluble 3·AuNPs the release of the drug is more favoured than 4·AuNPs. This can be seen as an advantage of 3·AuNPs, allowing its use as nanosystems with a high potential for use in biomedical applications. Additionally, two stability experiments in aqueous solution of 3·AuNPs before and after the incorporation of piroxicam were performed for a period of a week. The piroxicam-3·AuNPs were dissolved in three buffer solutions at either pH 5.5, 7.4 and 9, at room temperature and at 37°C.
Any case no macroscopic changes in the colloidal dispersions or variations in the SPR band and in the corresponding band of the drug were observed, which indicates that the 3·AuNPs are stable at different pH under the described conditions and they were not affected after the incorporation of the drug (see in the Supplementary Material Section 11 Tables S14 and S15, respectively).
Obviously, the complex would be coated AuNPs-piroxicam will be no longer existing when upon release conditions (see above, in vitro release studies).
Conclusions
In this work, we have synthesized and characterized three bis-pyridinium salts 1·2Br, 3·2Br, and 4·2Br with different chain lengths (18, 10 and 1 carbon atoms, respectively). Clearly, the length of the chain of the bis-pyridinium salt, is decisive for the amphiphile to act as promoter agent, since only 1·2Br containing 18 carbon atom chains are able to successfully generate 2·AuNPs following a biphasic method. [30] Consequently, the use of 3·2Br and 4·2Br for the synthesis of AuNPs is not favourable. The tetrahydropyridine moiety in 2 (resulting from the reduction of 1·2Br) is capable of reducing Au +3 to Au 0 , due to its spontaneous oxidation to the pyridinium salt, leading to the formation of 2'·AuNPs. The gold nanoparticles synthesized 1·AuNPs-4·AuNPs
and 2'·AuNPs proved stable and to have low polydispersity. Remarkably, 2'·AuNPs were found to be stable and monodisperse only when synthesized in the presence of KBr, indicating not only how crucial are the long chains in the amphiphile but the critical role of anions in their structure for the synthesis and stability of these nanoparticles, as described in previous report. [22, 33] The close proximity of the ligand 1·2Br to the metallic core was confirmed by different techniques such as MALDI-ToF MS and NMR spectroscopy. The ligand 1·2Br as well as 2·AuNPs and 3·AuNPs were neither cytotoxic nor genotoxic to the cell lines studied (3T3/NIH, HepG2 and CaCo-2) at the concentrations tested, when compared with similar structures using the same cell lines. [23] Additionally, 3·AuNPs and 4·AuNPs incorporating both 1·2Br and HS-C11-(EG)6-OH encapsulate piroxicam and piroxicam sodium salt, and release it in a sustained manner, suggesting that it diffuses from the complex instead of being released with an initial burst. This means that these vehicles could be used for long-term delivery of the drug. Moreover, the incorporation of piroxicam was evaluated and showed extremely low percentages of incorporation in both nonpyridinium coated nanoparticles 5·AuNPs and 6·AuNPs, indicating that the bis-pyridinium functionalization present in 2·AuNPs, 3·AuNPs and 4·AuNPs is by far the main factor determining the incorporation of the drug. Additionally, 3·AuNPs and 4·AuNPs showed the ability to incorporate piroxicam and piroxicam sodium salt respectively, with no significant differences in the amount of drug encapsulated. Moreover,the in vitro release of 3·AuNPs and 4·AuNPs at two different pH values (7.4 and 5.5) proves a faster release profile at pH 7.4, indicating their suitability as promising materials for delivery in physiological conditions. Finally, 3·AuNPs resulted stable at different pH under the described conditions and they were not affected after the incorporation of the drug . The next step in this research would be incorporation of other anionic drugs of higher therapeutic interest and testing the in vivo efficacy through alternative to oral administration in order to convert the AuNPs from a delivery vehicle into a theranostics tool.
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